首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Blood Advances

Blood Advances杂志,由American Society of Hematology出版,于2016年创刊,24 issues/year,出版语言English,ISSN:2473-9529,E-ISSN:2473-9537。

投稿咨询
Blood Advances
Blood Advances
Blood Advances
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
7.7
CiteScore
11.8
期刊收录
SCI、SCIE

Blood Advances(中文译名:《血液进展》),ISSN:2473-9529,EISSN:2473-9537,是American Society of Hematology出版的国际性学术期刊,创刊于2016年,以24 issues/year形式稳定发行,2026年总发文量约494篇。该刊采用非OA开放访问,学科归属为Medicine - Hematology。该刊是医学、血液学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达7.7,2025年期刊CiteScore为11.8,2025年期刊自引率约3.9%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Blood Advances长期聚焦医学、血液学及相关产业的技术应用前沿,在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、血液学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAEngland、Canada、GERMANY (FED REP GER)、France、Italy、Japan等为核心发文国家与地区;HARVARD UNIVERSITYUNIVERSITY OF TEXAS SYSTEM、DANA-FARBER CANCER INSTITUTE、UNIVERSITY OF PENNSYLVANIA、MEMORIAL SLOAN KETTERING CANCER CENTER、MAYO CLINIC、UNIVERSITY OF CALIFORNIA SYSTEM等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学
2区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学
2区
是 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学
2区
是 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 13 / 103

87.9

学科:HEMATOLOGY SCIE Q1 11 / 103

89.81

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 12 / 97

88.1

学科:HEMATOLOGY SCIE Q1 12 / 97

88.14


中国学者近期发文

1
Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphom

Author:Qin, Yao; Xia, Pan-Hui; Huang, Yao-Hui; Cheng, Shu; Liu, Jia-Ying; Gao, Xiao; Cai, Ming-Ci; Wang, Cong; Qiu, Yu-Ran; Hu, Song; Shi, Qing; Yang, Hao-Xu; Zhao, Jia-Yi; Wang, Lan; Xiong, Jie; Zhao, Wei-Li

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 7, pp. 2125-2141. DOI: 10.1182/bloodadvances.2025017682

2
Small-molecule inhibition of γ-glutamyl carboxylase reveals a novel anticoagulant strateg

Author:Shen, Guomin; Song, Dan; Li, Shixin; Chen, Xuejie; Richter, Catherine E.; Dong, Shixia; Guo, Yiming; Liu, Hongli; Shen, Yan; Hao, Zhenyu; Stafford, Darrel W.; Shavit, Jordan A.; Cao, Qing; Tie, Jian-Ke

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 7, pp. 2363-2375. DOI:

3
Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysi

Author:Shen, Jing; Zhang, Jingyi; Zhu, Zhengyu; Ma, Haobo; Zhang, Junpeng; Zhou, Fan; Tian, Hua; Liu, JingHua

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 7, pp. 2495-2505. DOI: 10.1182/bloodadvances.2025018474

4
RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran

Author:Gabrielsen, Anders; Ueckert, Sebastian; Nilsson, Catarina; Egnell, Ann-Charlotte; Fu, Jing; Wikstrom, Johannes; Svedlund, Sara; Friend, Richard; Zhang, Hongyan; Liang, Zicai; Gao, Shan; Gan, Li-Ming

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 7, pp. 2541-2548. DOI: 10.1182/bloodadvances.2025018348

5
TNIK as a molecular switch regulating platelet function in hemostasis and hyperlipidemia-associated thrombosi

Author:Li, Li; Chen, Xiaoyan; Li, Jingke; Deng, Xin; Sheng, Yilin; Lu, Linrong; Hu, Hu

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 6, pp. 1864-1878. DOI: 10.1182/bloodadvances.2025017737

6
Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mic

Author:Yu, Hongyin; Schroeder, Jocelyn A.; Mattson, Jeremy G.; Gao, Chunyan; Shi, Qizhen

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 6, pp. 1883-1896. DOI: 10.1182/bloodadvances.2025017921

7
Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 tria

Author:Jin, Yuanyuan; Cheng, Xin; Zhang, Xuezhong; Shi, Qinglin; Zhu, Yu; Li, Jianyong; Fan, Lei; Chen, Lijuan

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 6, pp. 2016-2022. DOI: 10.1182/bloodadvances.2025018945

8
Platelet dysfunction in chronic kidney disease arises from bone marrow remodeling and megakaryocyte reprogrammin

Author:Carminita, Estelle; Camacho, Virginia; Branfield, Siobhan; Walsey, Ethan; Barrachina, Maria N.; Tabang, Dylan N.; Lee, Dong H.; Becker, Isabelle C.; V. Brodsky, Sergey; Issa, Samer M.; Gendron, Nicolas; Machado, Sarah; Wolberg, Alisa S.; Steen, Hanno; Kerlin, Bryce; Machlus, Kellie R.; Zarjou, Abolfazl; Italiano, Joseph E

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 5, pp. 1444-1456. DOI: 10.1182/bloodadvances.2025017625

9
Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphom

Author:Li, Na; Liu, Yicen; Zhang, Linna; Guo, Saisai; Wu, Zhihao; Xu, Yan; Yang, Ming; Kong, Jixia; Che, Yuxuan; Shao, Kun; Yang, Hong

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 5, pp. 1722-1732. DOI: 10.1182/bloodadvances.2025016765

10
Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several year

Author:Liu, Qianwei; Fang, Fang; Xue, Huiwen; Wasterlid, Tove; Smedby, Karin Ekstrom; Liu, Xinyuan

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 4, pp. 1293-1300. DOI: 10.1182/bloodadvances.2024015776


在线咨询

Blood Advances

国际简称:BLOOD ADV参考译名:血液进展

年发文量:494 CiteScore:11.8 是否预警:否 Gold OA文章占比:99.75% 研究类文章占比:94.94%

杂志社联系方式:2021 L ST NW, SUITE 900, WASHINGTON, USA, DC, 20036

Blood Advances